Skip to content
OpenCapital
Get started

MiniMed Group MMED UNITED STATES — Net Sales

Similar metrics at other companies

Medtronic logo
MDTUnited States — Net Sales
$4.87B+7.1%
Globus Medical logo
GMEDUnited States — Net Sales
$604.89M+25.0%
Baxter International logo
BAXUnited States — Net Sales
$1.44B-3.7%
Bio-Rad Laboratories logo
BIOUNITED STATES — Net Sales
$229.8M-4.9%
The Cooper Companies, Inc. logo
COOUnited States — Net Sales
$547.8M+6.3%
Edwards Lifesciences logo
EWUnited States — Net Sales
$937.6M+11.8%

Other financials

Income statement

See full
Revenue$790.0M+15.0%
Gross profit$362.0M-8.4%
Operating income-$100.0M-576%
Net income-$119.0M-1,090%
EPS (diluted)-$0.47-1,075%

Balance sheet

See full
Cash & equivalents$10.0M0.0%
Total debt$61.0M—
Total equity$3.5B-0.7%
Total assets$4.3B—

Cash flow

See full
Operating cash flow-$27.0M-147%
CapEx$167.0M+22.8%
Free cash flow-$194.0M-146%

Valuation

See full
Market cap$3.86B—

Returns & leverage

See full
Debt / equity0×—
Current ratio1.6×—

Where this comes from

Reported directly by MiniMed Group in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: MiniMed Group ’s 10-Q, filed April 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about MiniMed Group 's united states — net sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MiniMed Group 's UNITED STATES — net sales?
MiniMed Group (MMED) reported UNITED STATES — net sales of $242M in Q1 2026.
What does UNITED STATES — net sales mean?
This metric represents the total revenue generated from the sale of medical devices and diabetes management solutions within the United States market. It reflects the company's commercial performance, market penetration, and demand for its insulin delivery and glucose monitoring products in this specific geographic region. Monitoring this figure helps investors assess the company's domestic growth trajectory and its ability to navigate the regulatory and competitive landscape of the U.S. healthcare sector.